Addex And Indivior Choose Clinical Candidates From Their GABAB Positive Allosteric Modulator Research Partnership
Portfolio Pulse from Benzinga Newsdesk
Addex and Indivior have selected clinical candidates from their GABAB Positive Allosteric Modulator research partnership. Addex could receive up to $330 million based on milestone achievements and royalties. Addex will also advance its own GABAB PAM program for chronic cough.
August 27, 2024 | 5:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indivior, in partnership with Addex, has selected clinical candidates for GABAB PAMs, potentially leading to significant milestone payments and royalties for Addex.
The selection of clinical candidates indicates progress in the partnership, which could lead to successful drug development and commercialization, benefiting Indivior.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80